The in vivo murine assay further demonstrates the efficacy of MSA-2, both as a standalone treatment and in combination with anti-PD-1, in effectively suppressing subcutaneous cervical tumor growth. This evidence concerns the gene PDCD1 and uterine cervix neoplasm.